AABB Outlines Vision for Blood, Biotherapies Community in Cures 2.0 Discussion Draft, ARPA-H RFI

July 21, 2021

AABB recently issued a communication to Congress that outlines the Association’s vision for the role of the blood and biotherapies community in the bipartisan Cures 2.0 discussion draft and Advanced Research Projects Agency for Health (ARPA-H) request for information (RFI). 

In a letter to Reps. Diana DeGette (D – Colo.) and Fred Upton (R – Mich.), AABB details how Cures 2.0 legislation can support a harmonized approach to cellular starting materials that are used to manufacture novel biotherapies; integrate the blood and biotherapies community into policies that advance a national testing and response strategy for future pandemics and public health responses; encourage improved communication and coordination between the Food and Drug Administration and the Centers for Medicare and Medicaid Services; and ensure that the ARPA-H can support research and development as well as projects that focus on the implementation of innovative technologies, processes and services related to blood, transfusion medicine and biotherapies. 

AABB’s vision for the blood and biotherapies community in the Cures 2.0 legislation and the ARPA-H RFI is informed by the AABB Advocacy Agenda. AABB encourages readers to visit AABB’s Advocacy web page for additional information on the Association’s additional efforts to expand access to biotherapies, promote a sustainable blood system and advance research to support access to safe, clinically effective transfusion medicine and biotherapies.